Pharmacological treatment patterns among patients with attention-deficit/ hyperactivity disorder: Retrospective claims-based analysis of a managed care population

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 977-989

  Christensen, Laura ^a   Sasane, Rahul ^b   Hodgkins, Paul ^b   Harley, Carolyn ^c   Tetali, Srinivas ^b  

^a I3 Innovus   (United States)

^b SHIRE   (United States)

^c I3 Innovus   (United States)

Author keywords

ADHD; Adherence; Persistence; Treatment patterns

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; SHORT ACTING DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; BILLING AND CLAIMS; CHILD; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGE FACTORS; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DRUG UTILIZATION REVIEW; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MALE; MEDICATION ADHERENCE; METHAMPHETAMINE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROPYLAMINES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 77949497812     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003673617     Document Type: Article

References (36)

1. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:71-78
2. Cohen P, Cohen J, Kasen S, et al. An epidemiological study of disorders in late childhood and adolescence-I. Age-and gender-specific prevalence. J Child Psychol Psychiatry 1993;34:851-867
3. Gomez-Beneyto M, Bonet A, Catala MA, et al. Prevalence of mental disorders among children in Valencia, Spain. Acta Psychiatr Scand 1994;89:352-357
4. Breton JJ, Bergeron L, Valla JP, et al. Quebec child mental health survey: prevalence of DSM-III-R mental health disorders. J Child Psychol Psychiatry 1999;40:375-384
5. Fayyad J, De GR, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-409
6. Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am Fam Physician 2000;62:2077-2082
7. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104-113
8. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004; 13(Suppl. 1):I/7-I/30
9. World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: World Health Organization, 1994
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR, 4th Edn. American Psychiatric Publishing, Inc., 2000
11. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164:942-948
12. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-248
13. Wolraich ML. Attention-deficit hyperactivity disorder. Semin Pediatr Neurol 2006;13:279-285
14. Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry 2006; 67(Suppl. 8):27-31
15. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115:e749-e757
16. National Institute for Health and Clinical Excellence. Attention deficit hyper-activity disorder: NICE clinical guideline 72. NICE 2008. Available at: http:// www.nice.org.uk/nicemedia/pdf/CG072NiceGuidelinev4.pdf [Last accessed 20 January 2010]
17. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon 2007;53:70-131
18. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: zresults from the national comorbidity survey replication. Biol Psychiatry 2005;57:1442-1451
19. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyper- activity disorder. Pediatrics 2001;108:1033-1044
20. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006;163:579-585
21. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
22. Detail-document #220214: Drug treatment for attention deficit hyperactivity disorder. Pharmacist's Letter/Prescriber's Letter 2006;22:220214
23. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12:248-253
24. Capp PK, Pearl PL, Conlon C. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. Expert Rev Neurother 2005;5:325-331
25. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006;27:1-10
26. Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/ hyperactivity disorder. Pediatrics 1999;103:e43
27. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-1373
28. Health insurance portability and accountability act of 1996. Public law 104-191, 104th Congress. U S Department of Health & Human Services, 1996. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/ HIPAALaw.pdf [Last accessed 12 January 2010]
29. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
30. Habel LA, Schaefer CA, Levine P, et al. Treatment with stimulants among youths in a large California health plan. J Child Adolesc Psychopharmacol 2005;15:62-67
31. Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylpheni-date: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008;22:603-611
32. Marcus SC, Wan GJ, Kemner JE, et al. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005;159:572-578
33. Sanchez RJ, Crismon ML, Barner JC, et al. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005;25:909-917
34. Perwien A, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Manag Care Pharm 2004;10:122-129
35. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry 2009; 48:51-59
36. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41:26S-49S